2021-04-012022-03-312022-03-31false06934724SMILE CLINIC UK LIMITED2022-08-17iso4217:GBPxbrli:pure069347242021-04-01069347242022-03-31069347242021-04-012022-03-31069347242020-04-01069347242021-03-31069347242020-04-012021-03-3106934724bus:SmallEntities2021-04-012022-03-3106934724bus:AuditExempt-NoAccountantsReport2021-04-012022-03-3106934724bus:AbridgedAccounts2021-04-012022-03-3106934724bus:PrivateLimitedCompanyLtd2021-04-012022-03-3106934724core:WithinOneYear2022-03-3106934724core:AfterOneYear2022-03-3106934724core:WithinOneYear2021-03-3106934724core:AfterOneYear2021-03-3106934724core:ShareCapital2022-03-3106934724core:SharePremium2022-03-3106934724core:RevaluationReserve2022-03-3106934724core:OtherReservesSubtotal2022-03-3106934724core:RetainedEarningsAccumulatedLosses2022-03-3106934724core:ShareCapital2021-03-3106934724core:SharePremium2021-03-3106934724core:RevaluationReserve2021-03-3106934724core:OtherReservesSubtotal2021-03-3106934724core:RetainedEarningsAccumulatedLosses2021-03-3106934724core:LandBuildings2022-03-3106934724core:PlantMachinery2022-03-3106934724core:Vehicles2022-03-3106934724core:FurnitureFittings2022-03-3106934724core:OfficeEquipment2022-03-3106934724core:NetGoodwill2022-03-3106934724core:IntangibleAssetsOtherThanGoodwill2022-03-3106934724core:ListedExchangeTraded2022-03-3106934724core:UnlistedNon-exchangeTraded2022-03-3106934724core:LandBuildings2021-03-3106934724core:PlantMachinery2021-03-3106934724core:Vehicles2021-03-3106934724core:FurnitureFittings2021-03-3106934724core:OfficeEquipment2021-03-3106934724core:NetGoodwill2021-03-3106934724core:IntangibleAssetsOtherThanGoodwill2021-03-3106934724core:ListedExchangeTraded2021-03-3106934724core:UnlistedNon-exchangeTraded2021-03-3106934724core:LandBuildings2021-04-012022-03-3106934724core:PlantMachinery2021-04-012022-03-3106934724core:Vehicles2021-04-012022-03-3106934724core:FurnitureFittings2021-04-012022-03-3106934724core:OfficeEquipment2021-04-012022-03-3106934724core:NetGoodwill2021-04-012022-03-3106934724core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3106934724core:ListedExchangeTraded2021-04-012022-03-3106934724core:UnlistedNon-exchangeTraded2021-04-012022-03-3106934724core:MoreThanFiveYears2021-04-012022-03-3106934724core:Non-currentFinancialInstruments2022-03-3106934724core:Non-currentFinancialInstruments2021-03-3106934724dpl:CostSales2021-04-012022-03-3106934724dpl:DistributionCosts2021-04-012022-03-3106934724dpl:AdministrativeExpenses2021-04-012022-03-3106934724core:LandBuildings2021-04-012022-03-3106934724core:PlantMachinery2021-04-012022-03-3106934724core:Vehicles2021-04-012022-03-3106934724core:FurnitureFittings2021-04-012022-03-3106934724core:OfficeEquipment2021-04-012022-03-3106934724core:NetGoodwill2021-04-012022-03-3106934724core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3106934724dpl:GroupUndertakings2021-04-012022-03-3106934724dpl:ParticipatingInterests2021-04-012022-03-3106934724dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3106934724core:ListedExchangeTraded2021-04-012022-03-3106934724dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3106934724core:UnlistedNon-exchangeTraded2021-04-012022-03-3106934724dpl:CostSales2020-04-012021-03-3106934724dpl:DistributionCosts2020-04-012021-03-3106934724dpl:AdministrativeExpenses2020-04-012021-03-3106934724core:LandBuildings2020-04-012021-03-3106934724core:PlantMachinery2020-04-012021-03-3106934724core:Vehicles2020-04-012021-03-3106934724core:FurnitureFittings2020-04-012021-03-3106934724core:OfficeEquipment2020-04-012021-03-3106934724core:NetGoodwill2020-04-012021-03-3106934724core:IntangibleAssetsOtherThanGoodwill2020-04-012021-03-3106934724dpl:GroupUndertakings2020-04-012021-03-3106934724dpl:ParticipatingInterests2020-04-012021-03-3106934724dpl:GroupUndertakingscore:ListedExchangeTraded2020-04-012021-03-3106934724core:ListedExchangeTraded2020-04-012021-03-3106934724dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-04-012021-03-3106934724core:UnlistedNon-exchangeTraded2020-04-012021-03-3106934724core:NetGoodwill2022-03-3106934724core:IntangibleAssetsOtherThanGoodwill2022-03-3106934724core:LandBuildings2022-03-3106934724core:PlantMachinery2022-03-3106934724core:Vehicles2022-03-3106934724core:FurnitureFittings2022-03-3106934724core:OfficeEquipment2022-03-3106934724core:AfterOneYear2022-03-3106934724core:WithinOneYear2022-03-3106934724core:ListedExchangeTraded2022-03-3106934724core:UnlistedNon-exchangeTraded2022-03-3106934724core:ShareCapital2022-03-3106934724core:SharePremium2022-03-3106934724core:RevaluationReserve2022-03-3106934724core:OtherReservesSubtotal2022-03-3106934724core:RetainedEarningsAccumulatedLosses2022-03-3106934724core:NetGoodwill2021-03-3106934724core:IntangibleAssetsOtherThanGoodwill2021-03-3106934724core:LandBuildings2021-03-3106934724core:PlantMachinery2021-03-3106934724core:Vehicles2021-03-3106934724core:FurnitureFittings2021-03-3106934724core:OfficeEquipment2021-03-3106934724core:AfterOneYear2021-03-3106934724core:WithinOneYear2021-03-3106934724core:ListedExchangeTraded2021-03-3106934724core:UnlistedNon-exchangeTraded2021-03-3106934724core:ShareCapital2021-03-3106934724core:SharePremium2021-03-3106934724core:RevaluationReserve2021-03-3106934724core:OtherReservesSubtotal2021-03-3106934724core:RetainedEarningsAccumulatedLosses2021-03-3106934724core:NetGoodwill2020-04-0106934724core:IntangibleAssetsOtherThanGoodwill2020-04-0106934724core:LandBuildings2020-04-0106934724core:PlantMachinery2020-04-0106934724core:Vehicles2020-04-0106934724core:FurnitureFittings2020-04-0106934724core:OfficeEquipment2020-04-0106934724core:AfterOneYear2020-04-0106934724core:WithinOneYear2020-04-0106934724core:ListedExchangeTraded2020-04-0106934724core:UnlistedNon-exchangeTraded2020-04-0106934724core:ShareCapital2020-04-0106934724core:SharePremium2020-04-0106934724core:RevaluationReserve2020-04-0106934724core:OtherReservesSubtotal2020-04-0106934724core:RetainedEarningsAccumulatedLosses2020-04-0106934724core:AfterOneYear2021-04-012022-03-3106934724core:WithinOneYear2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:CostValuation2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3106934724core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3106934724core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3106934724core:Non-currentFinancialInstrumentscore:CostValuation2021-03-3106934724core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-03-3106934724core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-03-3106934724bus:Director12021-04-012022-03-3106934724bus:Director22021-04-012022-03-3106934724bus:Director32021-04-012022-03-31

SMILE CLINIC UK LIMITED

Registered Number
06934724
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2022

SMILE CLINIC UK LIMITED
Company Information
for the year from 1 April 2021 to 31 March 2022

Directors

HUSSAIN, Adam Jamal, Dr
HUSSAIN, Isaac, Dr
HUSSAIN, Sabar, Dr

Registered Address

Fulford Lodge 1 Heslington Lane
Fulford
York
YO10 4HW

Registered Number

06934724 (England and Wales)
SMILE CLINIC UK LIMITED
Statement of Financial Position
31 March 2022

Notes

2022

2021

£

£

£

£

Fixed assets
Intangible assets7649,320717,360
Tangible assets815,56612,761
664,886730,121
Current assets
Stocks2,8002,850
Debtors10785,931786,184
Cash at bank and on hand1,010,980859,763
1,799,7111,648,797
Creditors amounts falling due within one year11(270,424)(152,917)
Net current assets (liabilities)1,529,2871,495,880
Total assets less current liabilities2,194,1732,226,001
Provisions for liabilities(2,957)(2,424)
Net assets2,191,2162,223,577
Capital and reserves
Called up share capital22
Profit and loss account2,191,2142,223,575
Shareholders' funds2,191,2162,223,577
The financial statements were approved and authorised for issue by the Board of Directors on 17 August 2022, and are signed on its behalf by:
HUSSAIN, Sabar, Dr
Director
Registered Company No. 06934724
SMILE CLINIC UK LIMITED
Notes to the Financial Statements
for the year ended 31 March 2022

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The principal activity of the company during the year was that of a dental practice.
4.Basis of measurement used in financial statements
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
5.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery20
Intangible assets policy
Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Stocks policy
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Revenue recognition policy
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year-end date is recognised by reference to the stage of completion.
Taxation policy
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
Going concern
In March 2020 the UK was impacted by the outbreak of Covid-19. The Government imposed significant restrictions at that time in an effort to manage the spread of the virus which resulted in the company having to review and change its working practices to ensure compliance with these restrictions. More latterly, the UK economy has been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
6.Employee information

20222021
Average number of employees during the year1613
7.Intangible assets

Total

£
Cost or valuation
At 01 April 211,360,800
At 31 March 221,360,800
Amortisation and impairment
At 01 April 21643,440
Charge for year68,040
At 31 March 22711,480
Net book value
At 31 March 22649,320
At 31 March 21717,360
8.Property, plant and equipment

Total

£
Cost or valuation
At 01 April 2154,222
Additions6,696
At 31 March 2260,918
Depreciation and impairment
At 01 April 2141,461
Charge for year3,891
At 31 March 2245,352
Net book value
At 31 March 2215,566
At 31 March 2112,761
9.Description of nature of transactions and balances with related parties
The directors operate a directors loan account with the company. At 31 March 2022 the Company owed the directors £86,933 (2021: £28,736). This was the maximum outstanding during the year. This amount is repayable upon demand.
10.Debtors

2022

2021

££
Trade debtors / trade receivables60,93161,184
Amounts owed by group undertakings725,000725,000
Total785,931786,184
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
11.Creditors within one year

2022

2021

££
Trade creditors / trade payables33,32317,257
Bank borrowings and overdrafts-458
Taxation and social security38,02664,464
Other creditors196,66468,315
Accrued liabilities and deferred income2,4112,423
Total270,424152,917
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.